Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GRI Bio Inc. (GRI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: GRI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22
1 Year Target Price $22
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -68.8% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.68M USD | Price to earnings Ratio 0.02 | 1Y Target Price 22 |
Price to earnings Ratio 0.02 | 1Y Target Price 22 | ||
Volume (30-day avg) 2 | Beta -1.8 | 52 Weeks Range 1.10 - 30.43 | Updated Date 09/16/2025 |
52 Weeks Range 1.10 - 30.43 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 90.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -98.68% | Return on Equity (TTM) -248.92% |
Valuation
Trailing PE 0.02 | Forward PE - | Enterprise Value -473298 | Price to Sales(TTM) - |
Enterprise Value -473298 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 2515300 | Shares Floating 2514827 |
Shares Outstanding 2515300 | Shares Floating 2514827 | ||
Percent Insiders 0.02 | Percent Institutions 0.78 |
Upturn AI SWOT
GRI Bio Inc.
Company Overview
History and Background
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory, fibrotic, and autoimmune diseases. Founded in 2020, it has progressed its lead asset through clinical trials.
Core Business Areas
- NKT Cell Modulators: Develops and commercializes novel NKT cell modulators for the treatment of autoimmune and inflammatory diseases.
Leadership and Structure
The company has a management team led by its CEO, with expertise in drug development and commercialization. The organizational structure includes research, clinical development, and business development functions.
Top Products and Market Share
Key Offerings
- GRI-0621: A novel, oral inhibitor of Interleukin-1 receptor-associated kinase 1 (IRAK1), being developed for idiopathic pulmonary fibrosis (IPF). Market share data is currently unavailable as the product is still in clinical development. Competitors include Boehringer Ingelheim (OFEV) and Roche (Esbriet).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and intense competition. There is a growing need for innovative therapies for autoimmune and inflammatory diseases.
Positioning
GRI Bio aims to address unmet medical needs in specific inflammatory and fibrotic diseases. Its approach focuses on modulating NKT cell function.
Total Addressable Market (TAM)
The global market for IPF treatment is projected to reach billions of USD. GRI Bio's positioning depends on the clinical success and market adoption of its lead compound, GRI-0621.
Upturn SWOT Analysis
Strengths
- Novel NKT cell modulation technology
- Strong intellectual property position
- Experienced management team
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Single lead asset concentration
- Reliance on clinical trial success
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into other inflammatory diseases
- Favorable regulatory environment for orphan drug development
Threats
- Clinical trial failures
- Competition from established therapies
- Changes in regulatory requirements
Competitors and Market Share
Key Competitors
- BMY
- MRK
- VRTX
Competitive Landscape
GRI Bio aims to differentiate itself through its NKT cell modulation technology. However, it faces competition from established therapies and larger pharmaceutical companies with more resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is represented by the advancement of the GRI-0621 product through clinical trials.
Future Projections: Future growth is dependent on the successful completion of clinical trials and potential commercialization or licensing deals.
Recent Initiatives: Recent initiatives include ongoing clinical trials for GRI-0621.
Summary
GRI Bio is an early-stage biopharmaceutical company with promising technology and a clinical asset targeting unmet needs. Success hinges on positive clinical trial outcomes and securing funding. While possessing innovative science, the company faces risks associated with drug development and competition from larger players.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, press releases, industry reports, analyst reports (where available).
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investing in biopharmaceutical companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GRI Bio Inc.
Exchange NASDAQ | Headquaters La Jolla, CA, United States | ||
IPO Launch date 2021-02-10 | Co-Founder, CEO, President & Director Dr. W. Marc Hertz Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://www.gribio.com |
Full time employees 3 | Website https://www.gribio.com | ||
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.